

Product Data Sheet

Product Name: Obrindatamab

Cat. No.: GC74586

Chemical Properties

Cas. No. 2069959-72-2

Formula

M.Wt

Solubility

Storage

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Obrindatamab

Background

Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer.

MGD009 (MGD009) binds human and cynomolgus monkey CD3 and B7-H3 with KD values of 13.9,

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

14.7, 24.6, and 30.2 nM for human CD3 ϵ / δ , cynomolgus CD3 ϵ / δ , human B7-H3-His, and cynomolgus B7-H3-His, respectively[1].Obrindatamab (0.01-1000 ng/mL; A498, U87, 22Rv1, and Detroit562 cells) mediates redirected killing of multiple B7-H3-expressing tumor lines[1].Obrindatamab (0.01-1000 ng/mL; PBMCs and A498 cells) mediated T-cell activation and proliferation is target antigen dependent[1].

Obrindatamab (MGD009; 0.004-1 mg/kg; i.v.) inhibits growth and tumor regression of B7-H3-expressing tumor xenografts in human T cell or PBMC-reconstituted mice[1].

References:

[1]. Paul M, et, al. MGD009, a B7-H3 x CD3 Bispecific Dual-Affinity Re-Targeting (DART®) Molecule Directing T Cells to Solid Tumors.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA